Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L... see more

Recent & Breaking News (NDAQ:ELDN)

Eledon Pharmaceuticals Strengthens Leadership Team with Chief Medical Officer and Chief Financial Officer Hires

GlobeNewswire March 15, 2021

Eledon Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 2, 2021

Eledon Pharmaceuticals to Present at 10th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 17, 2021

Eledon Pharmaceuticals to Participate in the Virtual Noble Capital Markets' Seventeenth Annual Investor / Equity Conference

GlobeNewswire January 19, 2021

Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

GlobeNewswire January 4, 2021

Novus Therapeutics Announces Results of Special Meeting of Stockholders

GlobeNewswire December 22, 2020

Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

Business Wire December 9, 2020

Novus Therapeutics Reports Third Quarter 2020 Financial Results

Business Wire November 16, 2020

Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

Business Wire November 10, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Business Wire November 2, 2020

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

Business Wire October 2, 2020

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

Business Wire September 15, 2020

Novus Therapeutics Announces Acquisition of Anelixis Therapeutics

Business Wire September 14, 2020

Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media

Business Wire June 1, 2020

Novus Therapeutics Reports First Quarter 2020 Financial Results

Business Wire May 15, 2020

Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results

Business Wire March 17, 2020

Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

Business Wire March 2, 2020

Novus Therapeutics Provides Update on OP0201

Business Wire January 13, 2020

Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Business Wire January 10, 2020

Novus Therapeutics to Participate in Two Investor Conferences

Business Wire November 29, 2019